五子衍宗丸联合脐疗治疗男性弱精症的临床效果研究
|
摘要
目的研究五子衍宗丸联合脐疗治疗男性弱精症患者的临床价值,为中医治疗男性弱精症提供循证医学依据。方法 89例男性弱精症患者,按照自愿原则分为对照组(41例)与研究组(48例)。对照组采用传统五子衍宗丸治疗,研究组在对照组基础上联合脐疗治疗。比较两组精子畸形指数(SDI)、DNA碎片率(DFI)、顶体完整率、α-糖苷酶、顶体反应率。结果治疗前,对照组SDI、α-糖苷酶、DFI、顶体完整率、顶体反应率分别为(1.97±0.24)%、(38.98±9.26)U/ml、(42.90±5.60)%、(34.18±9.85)%、(1.47±0.14)%,研究组SDI、α-糖苷酶、DFI、顶体完整率、顶体反应率分别为(1.98±0.23)%、(39.56±9.16)U/ml、(43.60±5.80)%、(33.41±10.21)%、(1.48±0.13)%,比较差异无统计学意义(P>0.05);治疗后,对照组SDI、α-糖苷酶、DFI、顶体完整率、顶体反应率分别为(1.51±0.37)%、(51.85±8.48)U/ml、(31.20±3.26)%、(71.61±21.24)%、(8.61±0.67)%,研究组SDI、α-糖苷酶、DFI、顶体完整率、顶体反应率分别为(1.08±0.41)%、(68.29±9.84)U/ml、(20.20±2.40)%、(95.62±15.10)%、(15.08±0.71)%;两组SDI、α-糖苷酶、DFI、顶体完整率、顶体反应率均优于治疗前,且研究组SDI、α-糖苷酶、DFI、顶体完整率、顶体反应率均优于对照组,差异具有统计学意义(P<0.05)。结论五子衍宗丸对男性弱精症患者治疗效果确切,而五子衍宗丸联合脐疗对男性弱精症患者的治疗效果更为显著,为中医治疗男性弱精症提供了新思路。
Objective To study the clinical value of Wuzi Yanzong pill combined with umbilical therapy in the treatment of male asthenospermia, and to provide evidence-based medical basis for the treatment of male asthenospermia by traditional Chinese medicine. Methods A total of 89 male asthenospermia patients were divided by voluntary principle into control group(41 cases) and research group(48 cases). The control group was treated with traditional Wuzi Yanzong pill, and the research group was treated with umbilical therapy on the basis of the control group. Comparison were made on sperm deformity index(SDI), DNA fragmentation index(DFI),acrosome integrity rate, α-glycosidase and acrosome reaction rate between the two groups. Results Before treatment, the control group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.97±0.24)%,(38.98±9.26)U/ml,(42.90±5.60)%,(34.18±9.85)% and(1.47±0.14)%, while the research group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.98±0.23)%,(39.56±9.16)U/ml,(43.60±5.80)%,(33.41±10.21)% and(1.48±0.13)%. Their difference was statistically significant(P>0.05). After treatment, the control group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.51±0.37)%,(51.85±8.48)U/ml,(31.20±3.26)%,(71.61±21.24)% and(8.61±0.67)%, while the research group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.08±0.41)%,(68.29±9.84)U/ml,(20.20±2.40)%,(95.62±15.10)% and(15.08±0.71)%. Both groups had better SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate than those before treatment, and the research group had better SDI, α-glycosidase,DFI, acrosome integrity rate and acrosome reaction rate than the control group. Their difference was statistically significant(P<0.05). Conclusion Wuzi Yanzong pill has a definite treatment effect on male asthenospermia patients, while Wuzi Yanzong pill combined with umbilical therapy has a more significant treatment effect on male asthenospermia patients, which provides a new idea for the treatment of male asthenospermia by traditional Chinese medicine.
Objective To study the clinical value of Wuzi Yanzong pill combined with umbilical therapy in the treatment of male asthenospermia, and to provide evidence-based medical basis for the treatment of male asthenospermia by traditional Chinese medicine. Methods A total of 89 male asthenospermia patients were divided by voluntary principle into control group(41 cases) and research group(48 cases). The control group was treated with traditional Wuzi Yanzong pill, and the research group was treated with umbilical therapy on the basis of the control group. Comparison were made on sperm deformity index(SDI), DNA fragmentation index(DFI),acrosome integrity rate, α-glycosidase and acrosome reaction rate between the two groups. Results Before treatment, the control group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.97±0.24)%,(38.98±9.26)U/ml,(42.90±5.60)%,(34.18±9.85)% and(1.47±0.14)%, while the research group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.98±0.23)%,(39.56±9.16)U/ml,(43.60±5.80)%,(33.41±10.21)% and(1.48±0.13)%. Their difference was statistically significant(P>0.05). After treatment, the control group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.51±0.37)%,(51.85±8.48)U/ml,(31.20±3.26)%,(71.61±21.24)% and(8.61±0.67)%, while the research group had SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate respectively as(1.08±0.41)%,(68.29±9.84)U/ml,(20.20±2.40)%,(95.62±15.10)% and(15.08±0.71)%. Both groups had better SDI, α-glycosidase, DFI, acrosome integrity rate and acrosome reaction rate than those before treatment, and the research group had better SDI, α-glycosidase,DFI, acrosome integrity rate and acrosome reaction rate than the control group. Their difference was statistically significant(P<0.05). Conclusion Wuzi Yanzong pill has a definite treatment effect on male asthenospermia patients, while Wuzi Yanzong pill combined with umbilical therapy has a more significant treatment effect on male asthenospermia patients, which provides a new idea for the treatment of male asthenospermia by traditional Chinese medicine.
引文
[1]李铮,张忠平,黄翼然.世界卫生组织男性不育标准化检查与诊疗手册.北京:人民卫生出版社,2007:8-10.
[2]张小庆,孙丹杰.五子衍宗丸联合复方玄驹胶囊治疗少弱精症患者30例疗效观察.中国性科学,2017,26(2):88-90.
[3]史亚磊,张敏建,程宛钧.五子衍宗汤与五子衍宗丸治疗弱精症临床对照研究.中国性科学,2017,26(12):73-75.
[4]安琪,邹练.五子衍宗丸治疗男性不育症的Meta分析.中国性科学,2015,24(1):84-85.
[5]王子濠,王满元.五子衍宗丸治疗男性不育症的研究进展.中国计划生育学杂志,2016,24(2):136-138.
[6]宋来新,张长城,袁丁,等.五子衍宗丸对生殖系统影响的研究进展.中成药,2016,38(7):1579-1581.
[7]韩亮,李海松,王彬,等.五子衍宗丸治疗精液异常男性不育60例临床观察.世界中西医结合杂志,2013,8(1):41-43.
[8]李南杭.五子衍宗丸治疗男性不育症60例.中国药业,201322(4):84-85.
[9]徐福平,张栋武,罗家怡,等.中医治疗弱精症患者与精子活动力的临床研究.中国医学创新,2017,14(20):1442-1445.
[10]范凯,肖友平,王波黄,等.五子衍宗丸联合左卡尼汀治疗少弱精子症的临床观察.内蒙古中医药,2016,(15):91.
[11]孙自学,门波,王祖龙,等.翁沥通胶囊联合五子衍宗丸和维生素C片治疗精液液化不良性不育症肾虚湿热型120例.中医研究,2016,29(10):15-17.
[12]徐洋涛,张瑜,许跃军,等.复方玄驹胶囊对弱精症患者精液质量、精子功能形态及精浆一氧化氮水平的影响.中国医药导报,2017,14(5):121-124.
[13]王惠洁.五子衍宗丸各药中治疗弱精症的化学成分及药理作用研究概况.陕西中医学院学报,2017,18(4):67-69.
[14]郭小桥,余波澜,周华,等.钙离子载体A23187诱发的精子顶体反应率、顶体酶总活性与精液参数及体外受精结局的关系研究.中华临床医师杂志(电子版),2014,23(3):8226-8228.
[15]郭洪寅,李姣,陈宇洲,等.脐疗剂型及其经皮吸收概述.中医外治杂志,2014,23(3):45-47.
[16]朱玲,靳芳.脐疗新探.中国民族民间医药,2016,25(14):56-57.
[17]王桐生,黄金玲,吴德玲,等.五子衍宗丸对少弱精子症模型大鼠精子线粒体膜电位及超微结构影响.中华男科学杂志,201319(5):446-450.
[18]杨欣,丁彩飞,颜志巾,等.五子衍宗方对生精障碍模型大鼠附睾精子参数及血清抑制素B的影响.中华中医药学刚,201230(2):371-373.
[19]曾晓,袁丁,王婷,等.五子衍宗方对实验性隐睾小鼠复位固定术后生精功能恢复的影响.中国中医基础医学杂志,201319(5):514-516.
[20]刘苗苗,张长城,贾亮亮,等.五子衍宗方对环磷酰胺致小鼠睾丸氧化损伤的保护作用.中成药,2013,35(12):2591-2597.
[2]张小庆,孙丹杰.五子衍宗丸联合复方玄驹胶囊治疗少弱精症患者30例疗效观察.中国性科学,2017,26(2):88-90.
[3]史亚磊,张敏建,程宛钧.五子衍宗汤与五子衍宗丸治疗弱精症临床对照研究.中国性科学,2017,26(12):73-75.
[4]安琪,邹练.五子衍宗丸治疗男性不育症的Meta分析.中国性科学,2015,24(1):84-85.
[5]王子濠,王满元.五子衍宗丸治疗男性不育症的研究进展.中国计划生育学杂志,2016,24(2):136-138.
[6]宋来新,张长城,袁丁,等.五子衍宗丸对生殖系统影响的研究进展.中成药,2016,38(7):1579-1581.
[7]韩亮,李海松,王彬,等.五子衍宗丸治疗精液异常男性不育60例临床观察.世界中西医结合杂志,2013,8(1):41-43.
[8]李南杭.五子衍宗丸治疗男性不育症60例.中国药业,201322(4):84-85.
[9]徐福平,张栋武,罗家怡,等.中医治疗弱精症患者与精子活动力的临床研究.中国医学创新,2017,14(20):1442-1445.
[10]范凯,肖友平,王波黄,等.五子衍宗丸联合左卡尼汀治疗少弱精子症的临床观察.内蒙古中医药,2016,(15):91.
[11]孙自学,门波,王祖龙,等.翁沥通胶囊联合五子衍宗丸和维生素C片治疗精液液化不良性不育症肾虚湿热型120例.中医研究,2016,29(10):15-17.
[12]徐洋涛,张瑜,许跃军,等.复方玄驹胶囊对弱精症患者精液质量、精子功能形态及精浆一氧化氮水平的影响.中国医药导报,2017,14(5):121-124.
[13]王惠洁.五子衍宗丸各药中治疗弱精症的化学成分及药理作用研究概况.陕西中医学院学报,2017,18(4):67-69.
[14]郭小桥,余波澜,周华,等.钙离子载体A23187诱发的精子顶体反应率、顶体酶总活性与精液参数及体外受精结局的关系研究.中华临床医师杂志(电子版),2014,23(3):8226-8228.
[15]郭洪寅,李姣,陈宇洲,等.脐疗剂型及其经皮吸收概述.中医外治杂志,2014,23(3):45-47.
[16]朱玲,靳芳.脐疗新探.中国民族民间医药,2016,25(14):56-57.
[17]王桐生,黄金玲,吴德玲,等.五子衍宗丸对少弱精子症模型大鼠精子线粒体膜电位及超微结构影响.中华男科学杂志,201319(5):446-450.
[18]杨欣,丁彩飞,颜志巾,等.五子衍宗方对生精障碍模型大鼠附睾精子参数及血清抑制素B的影响.中华中医药学刚,201230(2):371-373.
[19]曾晓,袁丁,王婷,等.五子衍宗方对实验性隐睾小鼠复位固定术后生精功能恢复的影响.中国中医基础医学杂志,201319(5):514-516.
[20]刘苗苗,张长城,贾亮亮,等.五子衍宗方对环磷酰胺致小鼠睾丸氧化损伤的保护作用.中成药,2013,35(12):2591-2597.